#China #Hangzhou #Chance Pharma #CXG87 #inhalation therapy

Chance Pharma Secures Important Funding

On March 17, 2025, Chance Pharmaceuticals, a pioneering clinical-stage biotech firm, disclosed the closing of a significant financing round aimed at propelling the development of their innovative inhalation therapies. This financial boost was supported by notable investors including Heda Health Fund and Qihang Venture Capital. The capital will primarily fuel Phase III clinical trials for CXG87, an advanced formulation of budesonide/formoterol inhalation powder, alongside the creation of several novel inhalation powder formulations.

Insights from Leadership

Dr. Donghao Chen, the visionary founder and CEO of Chance Pharma, expressed deep gratitude towards their investors, highlighting this funding as a crucial milestone for the company. He shared that this financing will play a pivotal role in fast-tracking the Phase III trials for CXG87, which holds remarkable clinical and commercial potential. Dr. Chen emphasized the importance of this funding in bolstering their capabilities in innovative inhalation drug development.

He stated, "The funding will significantly accelerate the Phase III clinical trials of CXG87, a product with great clinical and commercial potential. Furthermore, it will strengthen our innovative inhaled drug development capabilities, anchored by our proprietary spray-dried formulation platform." This illustrates Chance Pharma's commitment to addressing unmet clinical needs and driving forward innovative therapies that benefit patients globally.

Company's Technological Edge

Chance Pharma stands out for its dedication to the research and advancement of dry powder inhalation (DPI) therapies. Their development pipeline is underpinned by two essential technology platforms: milling and mixing, and spray drying. Their proprietary spray drying technique enables the conversion of biological macromolecules and less active medications into highly effective dry powder inhalation formulations that have the potential for deep lung and systemic delivery.

The company not only prides itself on meticulous research and development but also maintains advanced manufacturing facilities that comply with both FDA and EMA quality regulations. This commitment highlights Chance Pharma's robust capabilities in both R&D and production, making them a prominent player in the biotechnology landscape.

A Diverse Pipeline for Future Growth

Chance Pharmaceuticals is pushing boundaries with a dynamic portfolio that targets a variety of medical conditions including respiratory diseases, central nervous system disorders, and fibrotic diseases. Through independent innovation coupled with strategic partnerships, the company is well-positioned to deliver a broad range of programs designed to meet pressing healthcare needs.

The recent funding will assist in intensifying their collaborative efforts with both domestic and international partners. This strategy not only aims to enhance the efficacy of treatments but also ensures that they are accessible, safe, and cost-effective.

Looking Ahead

As Chance Pharma moves forward, the implementation of their strategic funding will accelerate their journey toward bringing innovative treatments to the market. With a unique blend of technological expertise and a commitment to patient-centered innovation, Chance Pharma is poised to make a significant impact in the field of inhalation therapies. Investors and stakeholders will be keenly watching as the company embarks on this critical phase with the promise of enhancing the lives of numerous patients around the world.

For further details, please visit Chance Pharmaceuticals.